Research outputs
2025
The pharmacokinetics, bio-distribution and therapeutic efficacy of a trimeric nanobody against SARS-CoV-2 in the Syrian golden hamster COVID-19 model
Investigation of anti-SARS CoV-2 multimeric bicyclic peptide inhibitors in a range of pre-clinical therapeutic settings
2024
Assessment of Favipiravir and Remdesivir in Combination for SARS-CoV-2 Infection in Syrian Golden Hamsters
Neary, M., Gallardo-Toledo, E., Sharp, J., Herriott, J., Kijak, E., Bramwell, C., . . . Owen, A. (2024). Assessment of Favipiravir and Remdesivir in Combination for SARS-CoV-2 Infection in Syrian Golden Hamsters. Viruses, 16(12). doi:10.3390/v16121838
Dose linearity studies of a glecaprevir and pibrentasvir long-acting injectable formulation in Sprague Dawley rats
Gallardo-Toledo, E., Arshad, U., Pertinez, H., Sharp, J., Herriott, J., Kijak, E., . . . Owen, A. (2024). Dose linearity studies of a glecaprevir and pibrentasvir long-acting injectable formulation in Sprague Dawley rats. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 90, 3-4. Retrieved from https://www.webofscience.com/
Preclinical pharmacokinetics of novel long-acting tenofovir alafenamide/bictegravir solid injectable in rats
Arshad, U., Barlow, E., Cox, H., Sharp, J., Pertinez, H., Herriott, J., . . . Owen, A. (2024). Preclinical pharmacokinetics of novel long-acting tenofovir alafenamide/bictegravir solid injectable in rats. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 90, 3. Retrieved from https://www.webofscience.com/
Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case
Tatham, L., Kipar, A., Sharp, J., Kijak, E., Herriott, J., Neary, M., . . . Owen, A. (2024). Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case. MICROBIOLOGY SPECTRUM, 12(8). doi:10.1128/spectrum.03916-23
Hyaluronidase impacts exposures of long-acting injectable paliperidone palmitate in rodent models.
Sotrovimab Lacks Efficacy in Treatment of Syrian Golden Hamsters Infected With SARS-CoV-2 BQ.1.1
Tatham, L., Sharp, J., Neary, M., Herriott, J., Kijak, E., Gallardo-Toledo, E., . . . Owen, A. (2024). Sotrovimab Lacks Efficacy in Treatment of Syrian Golden Hamsters Infected With SARS-CoV-2 BQ.1.1. Poster session presented at the meeting of The 31st Conference on Retroviruses and Opportunistic Infections (CROI 2024). Denver, US.
2023
Multivalent bicyclic peptides are an effective antiviral modality that can potently inhibit SARS-CoV-2
Gaynor, K. U. U., Vaysburd, M., Harman, M. A. J., Albecka, A., Jeffrey, P., Beswick, P., . . . James, L. C. C. (2023). Multivalent bicyclic peptides are an effective antiviral modality that can potently inhibit SARS-CoV-2. NATURE COMMUNICATIONS, 14(1). doi:10.1038/s41467-023-39158-1
Lack of antiviral activity of probenecid in vitro and in Syrian golden hamsters.
Box, H. J., Sharp, J., Pennington, S. H., Kijak, E., Tatham, L., Caygill, C. H., . . . Owen, A. (2023). Lack of antiviral activity of probenecid in vitro and in Syrian golden hamsters.. The Journal of antimicrobial chemotherapy, dkad362. doi:10.1093/jac/dkad362
Chemoprophylactic Assessment of Combined Intranasal SARS-CoV-2 Polymerase and Exonuclease Inhibition in Syrian Golden Hamsters
Gallardo-Toledo, E., Neary, M., Sharp, J., Herriott, J., Kijak, E., Bramwell, C., . . . Owen, A. (2023). Chemoprophylactic Assessment of Combined Intranasal SARS-CoV-2 Polymerase and Exonuclease Inhibition in Syrian Golden Hamsters. VIRUSES-BASEL, 15(11). doi:10.3390/v15112161
Evaluation of Nafamostat as Chemoprophylaxis for SARS-CoV-2 Infection in Hamsters
Neary, M., Sharp, J., Gallardo-Toledo, E., Herriott, J., Kijak, E., Bramwell, C., . . . Owen, A. (2023). Evaluation of Nafamostat as Chemoprophylaxis for SARS-CoV-2 Infection in Hamsters. VIRUSES-BASEL, 15(8). doi:10.3390/v15081744
Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case.
FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2
Brevini, T., Maes, M., Webb, G. J., John, B. V., Fuchs, C. D., Buescher, G., . . . Sampaziotis, F. (2023). FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2. NATURE, 615(7950), 134-+. doi:10.1038/s41586-022-05594-0